Humulin R (Insulin Human (Rdna))

Humulin R is indicated for the treatment of diabetes mellitus where rapid insulin replacement is required to control post‑prandial glucose excursions. It may be used as part of a basal‑bolus regimen or in combination with other antidiabetic agents to achieve individualized glycemic targets.

• Initiation of insulin therapy in newly diagnosed type 1 diabetes.
• Supplemental rapid‑acting insulin for type 2 diabetes patients inadequately controlled on oral agents.
• Management of hyperglycemia during meals (prandial insulin).
• Adjustment of insulin dose during illness, stress, or steroid therapy.
• Use in insulin pump therapy where rapid‑acting insulin is required.

• Humulin R contains recombinant human insulin that binds to insulin receptors on the surface of muscle, adipose, and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3K‑Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, and inhibiting hepatic gluconeogenesis. The rapid onset of action reflects its quick absorption from the subcutaneous tissue, thereby lowering blood glucose concentrations.

Like all insulin preparations, Humulin R may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia (low blood glucose) presenting as sweating, tremor, or confusion.
• Injection‑site reactions such as redness, swelling, or mild pain.
• Lipodystrophy including lipohypertrophy at repeated injection sites.
• Allergic skin manifestations like urticaria or localized itching.
• Weight gain due to increased anabolic effects.
• Nausea or gastrointestinal discomfort.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Anaphylactic reactions with respiratory distress, hives, or angioedema.
• Edema or heart failure exacerbation in susceptible patients.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Hypersensitivity leading to serum sickness–like reaction.
• Severe allergic reaction requiring emergency medical attention.

When prescribing Humulin R, clinicians should evaluate patient‑specific factors and monitor for conditions that could modify insulin requirements or increase risk of adverse events.

• Assess renal and hepatic function, as impairment may prolong insulin action.
• Adjust dose during pregnancy, lactation, or in pediatric patients under medical supervision.
• Monitor for hypoglycemia when patients engage in vigorous exercise or alter meal patterns.
• Use caution in patients with cardiovascular disease or heart failure due to potential fluid retention.
• Review concomitant medications that affect glucose metabolism before initiating therapy.
• Educate patients on proper injection technique and rotation of sites to prevent lipohypertrophy.

Humulin R can interact with other medicines that influence blood glucose levels or insulin pharmacokinetics, requiring dose adjustments or monitoring.

Avoid

• Concurrent use of other rapid‑acting insulins without dose reduction, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unnoticed low glucose.
• High‑dose corticosteroids that markedly raise blood glucose, potentially overwhelming insulin effect.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which may potentiate hypoglycemia.
• Thiazide diuretics that can increase insulin resistance and alter glucose control.
• ACE inhibitors or ARBs, as they may affect renal function and insulin clearance.
• Alcohol consumption, which can cause delayed hypoglycemia after insulin administration.